| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0002523 | Leukocyte migration involved in inflammatory response | Increases phenotype | PMID:34826398 |
| GO:0006874 | Cellular calcium ion homeostasis | Affects phenotype | PMID:34826398 |
| GO:0006915 | Apoptotic process | Increases phenotype | PMID:26784575 |
| GO:0006954 | Inflammatory response | Increases phenotype | PMID:34826398 |
| GO:0007253 | Cytoplasmic sequestering of nf-kappab | Decreases phenotype | PMID:31226360 |
| GO:0008219 | Cell death | Increases phenotype | PMID:23626763 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:26784575 |
| GO:0016477 | Cell migration | Affects phenotype | PMID:22683935 |
| GO:0030214 | Hyaluronan catabolic process | Increases phenotype | PMID:31226360 |
| GO:0031052 | Programmed dna elimination by chromosome breakage | Increases phenotype | PMID:30439388 |
| GO:0032980 | Keratinocyte activation | Increases phenotype | PMID:26796489; PMID:31226360 |
| GO:0036091 | Positive regulation of transcription from rna polymerase ii promoter in response to oxidative stress | Increases phenotype | PMID:26796489; PMID:32335162 |
| GO:0043065 | Positive regulation of apoptotic process | Increases phenotype | PMID:23172806; PMID:35363429 |
| GO:0043303 | Mast cell degranulation | Increases phenotype | PMID:34826398 |
| GO:0045576 | Mast cell activation | Increases phenotype | PMID:34826398 |
| GO:0045930 | Negative regulation of mitotic cell cycle | Increases phenotype | PMID:26784575 |
| GO:0046330 | Positive regulation of jnk cascade | Increases phenotype | PMID:23172806 |
| GO:0048312 | Intracellular distribution of mitochondria | Affects phenotype | PMID:35363429 |
| GO:0051726 | Regulation of cell cycle | Increases phenotype | PMID:23172806 |
| GO:0051881 | Regulation of mitochondrial membrane potential | Affects phenotype | PMID:26784575 |
| GO:0060467 | Negative regulation of fertilization | Increases phenotype | PMID:35363429 |
| GO:0060473 | Cortical granule | Affects phenotype | PMID:35363429 |
| GO:0070373 | Negative regulation of erk1 and erk2 cascade | Increases phenotype | PMID:23172806 |
| GO:1900127 | Positive regulation of hyaluronan biosynthetic process | Increases phenotype | PMID:31226360 |
| GO:1900745 | Positive regulation of p38mapk cascade | Increases phenotype | PMID:23172806 |
| GO:1903409 | Reactive oxygen species biosynthetic process | Increases phenotype | PMID:26784575 |
| GO:1903428 | Positive regulation of reactive oxygen species biosynthetic process | Increases phenotype | PMID:23172806; PMID:35363429 |
| GO:2000355 | Negative regulation of ovarian follicle development | Increases phenotype | PMID:35363429 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.